| Name | Title | Contact Details |
|---|
Lygos employs cutting edge synthetic biology techniques to generate microbial catalysts to convert agricultural feedstocks into fine and commodity chemicals. Our robust high throughput screening and strain construction facilitates the rapid optimization of pathways to convert cheap and renewable feedstock to high value chemicals.
At Ensoma, we believe every person, no matter where they are in the world, should have access to innovative technologies that are changing the way we treat disease.
Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies.
Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis. The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.
Brampton Cosmetic Surgery is a Brampton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.